People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | — | Biotechnology | Series D+ | $614.0M | $8.0B | 2015 |
| SonoThera, Inc. | — | Biotechnology | Series B | $30.4M | $550.9M | 2022 |
Tom Willis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tom Willis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Asish Xavier | 1 | 18 |
| Brian Halak | 1 | 10 |
| Chad Robins | 1 | 5 |
| Lee Huntsman | 1 | 5 |
| Peter Neupert | 1 | 4 |
| Michael Davidson | 1 | 4 |
| Arnold Levine | 1 | 4 |
| John Stuelpnagel | 1 | 3 |
| Lori Hu | 1 | 3 |
| Chris Carlson | 1 | 2 |
| Harlan Robins | 1 | 2 |
| Chad Cohen | 1 | 2 |
| Kenneth Greenberg | 1 | 2 |
| Craig Weissman | 1 | 2 |
| Andris Zoltners | 1 | 1 |
| Andy Zoltners | 1 | 1 |
| Rob Rosen | 1 | 1 |
| Kathleen Determann | 1 | 1 |
| Dean Schorno | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.